HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Infant Formula Supply Chain Strategy Delivered

Executive Summary

FDA immediate actions include ensuring providers know they’re required to develop redundancy risk management plans, enhancing inspections of manufacturers, including by expanding and improving training for investigators, and expediting reviews of premarket submissions for new products.

You may also be interested in...



Abbott Speaks Lingo Wearables For Future Growth, Posts Formula As Current Consumer Sales Driver

Lingo’s target “is to do something that not a lot of well-established health care companies do, which is to create a product that's really targeting a healthy population and a healthy population that wants to stay healthy,” says CEO Robert Ford.

In Food Programs Restructuring, US FDA Has Designs On Clear Priorities, Chain Of Command

Following reviews prompted largely by formula supply crisis, FDA will move Center for Food Safety and Applied Nutrition and commissioner’s Office of Food Programs and Response to Human Foods Program headed by deputy commissioner. Office of Regulatory Affairs' structure also changing “to support the FDA organization as a whole,” says Commissioner Califf.

Congress Boosts FDA Food Safety Budget Nearly $700M, Orders Reports On Formula Supply

Appropriators are “concerned by the fragility of the infant formula supply chain and the detrimental health impacts that can arise from shortage of these regulated products.” Their report published with FY2023 omnibus appropriations also asks for list of Russian firms with pending NDAs, including OTCs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel